Abstract:<section class="article-section article-section__abstract" lang="en" data-lang="en" id="section-1-en"> <h3 class="article-section__header main main">Abstract</h3> <div class="article-section__content en main"> <p>The success of targeted drug therapies for treating cancer patients has been largely attracted broad attention both in academic community and social society. However, rapidly developed acquired resistance is becoming a newly recognized major challenge to make these therapies continuously efficiency. Metformin is one of well‐known natural compounds derived from French plant lilac with low toxicity. Our previous work has highlighted research progress of combination of clinically applied chemotherapies and metformin via different mechanisms. In meantime, we launched a brave study to combine metformin with the small targeted drug, Gefitinib to treat bladder cancer via intravesical administration. Thus, in this mini‐review, we summarize recent achievements combining metformin with various targeted therapies. This work directs the potential clinical future by selecting the available cancer patients and providing precise medicine via combination of metformin and targeted drugs through overcoming their resistance and enhancing therapeutic efficacies.</p> <p>This article is protected by copyright. All rights reserved.</p>

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is the rapidly developing acquired drug - resistance phenomenon in cancer patients during targeted drug treatment. It proposes a new strategy to overcome drug - resistance and improve treatment effects by combining metformin with targeted drugs. Specifically, the research focuses on the synergistic effects and their potential mechanisms of metformin in combination with several different types of targeted drugs (such as small - molecule inhibitors and antibodies), in order to provide new directions for clinical applications, especially for those patients who have already developed resistance to monotherapy. The specific examples mentioned in the paper include: - **Metformin and gefitinib**: Studies have shown that metformin can enhance the treatment effect of gefitinib on non - small - cell lung cancer (NSCLC), reduce tumor growth, and reverse the drug - resistance of gefitinib. - **Metformin and sorafenib**: The combination of metformin and sorafenib shows a synergistic effect in the treatment of hepatocellular carcinoma (HCC), not only inhibiting tumor growth but also reducing lung metastasis. - **Metformin and everolimus**: Research indicates that the combination of metformin and everolimus significantly prolongs the progression - free survival (PFS) in the treatment of pancreatic neuroendocrine tumors. However, it should be noted that this combination may increase adverse reactions in patients in some cases. - **Metformin and monoclonal antibodies**: For example, the combination of metformin with trastuzumab or bevacizumab also shows positive effects in the treatment of breast cancer and ovarian cancer, being able to further inhibit tumor growth and angiogenesis. Overall, this paper aims to explore how metformin, as a low - toxicity broad - spectrum anti - cancer drug, can improve treatment effects and overcome drug - resistance through combination with existing targeted drugs, thereby providing more effective treatment options for cancer patients.

Novel application of metformin combined with targeted drugs on anticancer treatment

Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy

Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect

Non-coding RNAs as potential targets in metformin therapy for cancer

Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend

Metformin Inhibited Esophageal Squamous Cell Carcinoma Proliferation in Vitro and in Vivo and Enhanced the Anti-Cancer Effect of Cisplatin

Metformin: From Diabetes to Cancer—Unveiling Molecular Mechanisms and Therapeutic Strategies

Metformin Synergistically Suppress Tumor Growth with Doxorubicin and Reverse Drug Resistance by Inhibiting the Expression and Function of P-glycoprotein in MCF7/ADR Cells and Xenograft Models

Enhancement of targeted therapy in combination with metformin on human breast cancer cell lines

Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing

Metformin: A Novel but Controversial Drug in Cancer Prevention and Treatment

Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin

A New Role for an Old Drug: Metformin Targets MicroRNAs in Treating Diabetes and Cancer

Synergistic anticancer effects of doxorubicin and metformin combination therapy: A systematic review

Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice

Molecular Mechanisms of Metformin for Diabetes and Cancer Treatment

Metformin in the treatment of colorectal cancer and neuroendocrine tumours

Synergistic therapeutic effects of metformin at a clinically relevant dosage in combination with chemotherapy via the AKT/mTOR pathway on ovarian cancer

Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT-FOXO3 signalling pathway

Advances in Research on the Anticancer Properties and Mechanisms of Metformin in Lung Cancer

Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes